EUVIMEDEUVIMED entdecken
Crossref

Technetium-99m-labeled HBsAg-conjugated anionic linear–globular dendrimers: radiolabeling and preclinical biodistribution

Hasti Nequi Marnani, Tahereh Zadeh Mehrizi, Mehdi Shafiee Ardestani, Maryam Davoudi, Nazanin Ajdary, Mehdi Mirzaei

DARU Journal of Pharmaceutical Sciences · 10.11.2026 · 35 (1)

DOI: 10.1007/s40199-026-00689-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift DARU Journal of Pharmaceutical Sciences, online erschienen am 10.11.2026. Verfasst von Hasti Nequi Marnani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran. Hauptthemen laut MEDLINE: Technetium, Dendrimers, Hepatitis B Surface Antigens, Radiopharmaceuticals. Die Arbeit nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Radiolabeling of nanocarriers can facilitate preclinical evaluation of their biodistribution and organ accumulation in healthy mice. OBJECTIVES: HBsAg was conjugated to G2-ALGD using carbodiimide chemistry and subsequently radiolabeled with technetium-99m (D-HBsAg-⁹⁹ᵐTc). The resulting nanoplatform was characterized in terms of its physicochemical properties, radiochemical purity, and preliminary cytocompatibility. Its in vivo biodistribution was evaluated in BALB/c mice using single-photon emission computed tomography (SPECT) imaging and ex vivo radiometry. RESULTS: D-HBsAg-⁹⁹ᵐTc nanotracers were 148.3 ± 24.5 nm in size and showed a zeta potential of + 3.65 mV. FTIR verified amide bond formation at 1649 cm⁻¹ between the dendrimer's carboxyl groups and HBsAg's amino groups. They showed no significant cytotoxicity in HFF-2 cells up to 100 µg/mL after 24 h. These nanoconjugates achieved a radiochemical purity of 95.83% and remained radiochemically stable for 24 h without detectable technetium leakage. Ex vivo biodistribution and SPECT imaging demonstrated significantly greater hepatic accumulation of D-HBsAg-⁹⁹ᵐTc than free ⁹⁹ᵐTc (22.89 ± 0.45 vs. 0.88 ± 0.42%ID/g, P < 0.05). Compared with HBsAg-⁹⁹ᵐTc, D-HBsAg-⁹⁹ᵐTc exhibited comparable liver uptake (22.89 ± 0.45 vs. 20.78 ± 4.23%ID/g) but substantially lower splenic (6.34 ± 0.21 vs. 11.66 ± 0.28%ID/g) and gastrointestinal accumulation, indicating improved hepatic accumulation and reduced off-target distribution. CONCLUSION: This nanoplatform represents a promising technetium-99m-labeled nano-tracer and demonstrated preferential hepatic accumulation in healthy mice, supporting its feasibility for preclinical biodistribution studies. Future studies should evaluate its immunogenicity and antiviral activity in appropriate HBV animal models to determine whether it may have applications beyond preclinical biodistribution imaging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TechnetiumDendrimersHepatitis B Surface AntigensRadiopharmaceuticalsNanoconjugatesAnimalsTissue DistributionMice, Inbred BALB CTomography, Emission-Computed, Single-PhotonMiceHumansCell LineMale

Stichwörter der Autor:innen

CharacterizationDendrimersHepatitis B surface antigensRadiolabelingTechnetium-99m

Substanzen

TechnetiumDendrimersHepatitis B Surface AntigensRadiopharmaceuticalsNanoconjugates

Autor:innen und Institutionen

  • Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.
  • Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Islamic Republic of Iran.
  • Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Islamic Republic of Iran. mehrizi.t@iums.ac.ir.
  • Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran. shafieeardestani@gmail.com.
  • Research Center for Nuclear Medicine, Shariati Hospital, Tehran, Islamic Republic of Iran. shafieeardestani@gmail.com.
  • Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.

Zitieren

APA

Marnani, H. N., Mehrizi, T. Z., Ardestani, M. S., Davoudi, M., Ajdary, N., & Mirzaei, M. (2026). Technetium-99m-labeled HBsAg-conjugated anionic linear–globular dendrimers: radiolabeling and preclinical biodistribution. DARU Journal of Pharmaceutical Sciences, 35(1). https://doi.org/10.1007/s40199-026-00689-9

Vancouver

Marnani HN, Mehrizi TZ, Ardestani MS, Davoudi M, Ajdary N, Mirzaei M. Technetium-99m-labeled HBsAg-conjugated anionic linear–globular dendrimers: radiolabeling and preclinical biodistribution. DARU Journal of Pharmaceutical Sciences. 2026;35(1). doi:10.1007/s40199-026-00689-9

BibTeX
@article{Marnani2026,
  author = {Marnani, Hasti Nequi and Mehrizi, Tahereh Zadeh and Ardestani, Mehdi Shafiee and Davoudi, Maryam and Ajdary, Nazanin and Mirzaei, Mehdi},
  title = {Technetium-99m-labeled HBsAg-conjugated anionic linear–globular dendrimers: radiolabeling and preclinical biodistribution},
  journal = {DARU Journal of Pharmaceutical Sciences},
  year = {2026},
  volume = {35},
  number = {1},
  doi = {10.1007/s40199-026-00689-9}
}
Kostenlos starten →